We are a holding and investment company
Novo Holdings is a holding and investment company, responsible for managing the assets and wealth of the Novo Nordisk Foundation. Headquartered in Copenhagen and wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder in Novo Nordisk and Novozymes (the “Novo Group” companies) and manages an investment portfolio (the “Investment Portfolio”), with a long-term return perspective. The Novo Holdings Investment Portfolio is comprised of Life Science Investments and Capital Investments. We aspire to be a leading responsible investor, recognised for delivering strong financial returns and positive societal impact. Novo Holdings operates from offices in Copenhagen, London, Boston, San Francisco, Singapore and Shanghai. As of year-end 2021, Novo Holdings had total assets of $106 billion.
Novo Holdings is among the world’s leading life science investors and invests in companies at all stages of development. Life Science Investments includes Seed Investments, Venture Investments, Growth Investments and Principal Investments. In 2021 Life Science Investments invested $2.2 billion in 71 companies. Capital Investments manages a diversified portfolio of equities, bonds, real estate and infrastructure assets, as well as private equity investments.
The purpose of Novo Holding is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
For more information, download our fact sheet.